nach oben

Erschienen in:

26.12.2022

The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument

verfasst von: Qiang Zheng, Ingrid A. Cox, Barbara de Graaff, Julie A. Campbell, Tamera J. Corte, Ian Glaspole, Vidya Navaratnam, Peter Hopkins, Chris Zappala, Hasnat Ahmad, Ting Zhao, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer

Erschienen in: Quality of Life Research | Ausgabe 6/2023

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Purpose

Little is known about the impact of co-morbidities on health-related quality of life (HRQoL) for people with idiopathic pulmonary fibrosis (IPF). We aimed to investigate the relative contribution of co-morbidities to HRQoL of people with IPF.

Methods

N = 157 participants were recruited from the Australian IPF Registry (AIPFR). Health state utilities (HSUs), and the super-dimensions of physical and psychosocial scores were measured using the Assessment of Quality of Life-8-Dimensions (AQoL-8D). The impact of co-morbidities on HRQoL was investigated using linear regression and general dominance analyses.

Results

A higher number of co-morbidities was associated with lower HSUs (p trend = 0.002). Co-morbidities explained 9.1% of the variance of HSUs, 16.0% of physical super-dimensional scores, and 4.2% of psychosocial super-dimensional scores. Arthritis was associated with a significant reduction on HSUs (β = − 0.09, 95% confidence interval [CI] − 0.16 to − 0.02), largely driven by reduced scores on the physical super-dimension (β = − 0.13, 95% CI − 0.20 to − 0.06). Heart diseases were associated with a significant reduction on HSUs (β = − 0.09, 95% CI − 0.16 to − 0.02), driven by reduced scores on physical (β = − 0.09, 95% CI − 0.16 to − 0.02) and psychosocial (β = -0.10, 95% CI − 0.17 to − 0.02) super-dimensions.

Conclusions

Co-morbidities significantly impact HRQoL of people with IPF, with markedly negative impacts on their HSUs and physical health. A more holistic approach to the care of people with IPF is important as better management of these co-morbidities could lead to improved HRQoL in people with IPF.

Vorheriger Artikel Correction: Development of a standard set of PROs and generic PROMs for Dutch medical specialist care

Nächster Artikel Comparative analysis of pediatric anxiety measures in clinical sample: evaluation of the PROMIS pediatric anxiety short forms

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Nur mit Berechtigung zugänglich

Tran, T., Šterclová, M., Mogulkoc, N., Lewandowska, K., Müller, V., Hájková, M., Kramer, M. R., Jovanović, D., Tekavec-Trkanjec, J., Studnicka, M., Stoeva, N., Hejduk, K., Dušek, L., Suissa, S., & Vašáková, M. (2020). The European MultiPartner IPF registry (EMPIRE): Validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 21(1), 1–11.CrossRef

Strand, M. J., Sprunger, D., Cosgrove, G. P., Fernandez-Perez, E. R., Frankel, S. K., Huie, T. J., Olson, A. L., Solomon, J., Brown, K. K., & Swigris, J. J. (2014). Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest, 146(3), 775–785.CrossRefPubMedPubMedCentral

Cox, I. A., Otahal, P., Graaff, B., Corte, T. J., Moodley, Y., Zappala, C., Glaspole, I., Hopkins, P., Macansh, S., Walters, E. H., & Palmer, A. J. (2021). Incidence, prevalence and mortality of idiopathic pulmonary fibrosis in Australia. Respirology, 27(3), 209–216.CrossRefPubMed

Sheth, J. S., Xia, M., Murray, S., Martinez, C. H., Meldrum, C. A., Belloli, E. A., Salisbury, M. L., White, E. S., Holtze, C. H., & Flaherty, K. R. (2019). Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 148, 6–12.CrossRefPubMedPubMedCentral

Caminati, A., Lonati, C., Cassandro, R., Elia, D., Pelosi, G., Torre, O., Zompatori, M., Uslenghi, E., & Harari, S. (2019). Comorbidities in idiopathic pulmonary fibrosis: An underestimated issue. European Respiratory Review, 28(153), 190044.CrossRefPubMedPubMedCentral

Alhamad, E. H., Cal, J. G., Alrajhi, N. N., Aharbi, W. M., AlRikabi, A. C., & AlBoukai, A. A. (2020). Clinical characteristics, comorbidities, and outcomes in patients with idiopathic pulmonary fibrosis. Annals of Thoracic Medicine, 15(4), 208–214.CrossRefPubMedPubMedCentral

Caminati, A., Madotto, F., Conti, S., Cesana, G., Mantovani, L., & Harari, S. (2021). The natural history of idiopathic pulmonary fibrosis in a large European population: The role of age, sex and comorbidities. Internal and Emergency Medicine, 16(7), 1793–1802.CrossRefPubMed

Torrisi, S. E., Ley, B., Kreuter, M., Wijsenbeek, M., Vittinghoff, E., Collard, H. R., & Vancheri, C. (2019). The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: A multicentre observational study. European Respiratory Journal, 53(3), 1801587.CrossRefPubMed

Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., King, T. E., Jr., & Collard, H. R. (2012). A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of Internal Medicine, 156(10), 684–691.CrossRefPubMed

10.

Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford University Press.

11.

Glaspole, I. N., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S., Hopkins, P. M., Macansh, S., Mahar, A., Moodley, Y. P., Paul, E., Reynolds, P. N., Walters, E. H., Zappala, C. J., & Corte, T. J. (2017). Health-related quality of life in idiopathic pulmonary fibrosis: Data from the Australian IPF Registry. Respirology, 22(5), 950–956.CrossRefPubMed

12.

Cox, I. A., Borchers Arriagada, N., De Graaff, B., Corte, T. J., Glaspole, I., Lartey, S., Walters, E. H., & Palmer, A. J. (2020). Health-related quality of life of patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. European Respiratory Review, 29(158), 200154.CrossRefPubMedPubMedCentral

13.

Richardson, J., Khan, M. A., Iezzi, A., & Maxwell, A. (2015). Comparing and Explaining Differences in the Magnitude, Content, and Sensitivity of Utilities Predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D Multiattribute Utility Instruments. Medical Decision Making, 35(3), 276–291.CrossRefPubMed

14.

Richardson, J., Sinha, K., Iezzi, A., & Khan, M. A. (2014). Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Quality of Life Research, 23(8), 2395–2404.CrossRefPubMed

15.

Cox, I. A., De Graaff, B., Ahmed, H., Campbell, J., Otahal, P., Corte, T. J., Glaspole, I., Moodley, Y., Goh, N., Macansh, S., Walters, E. H., & Palmer, A. J. (2021). The impact of idiopathic pulmonary fibrosis on health state utility values: Evidence from Australia. Quality of Life Research, 30(9), 2615–2632.CrossRefPubMed

16.

Kreuter, M., Swigris, J., Pittrow, D., Geier, S., Klotsche, J., Prasse, A., Wirtz, H., Koschel, D., Andreas, S., Claussen, M., Grohé, C., Wilkens, H., Hagmeyer, L., Skowasch, D., Meyer, J. F., Kirschner, J., Gläser, S., Herth, F. J. F., Welte, T., … Behr, J. (2017). Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: Insights-IPF registry. Respiratory Research, 18(1), 139.CrossRefPubMedPubMedCentral

17.

Jo, H. E., Glaspole, I., Grainge, C., Goh, N., Hopkins, P. M., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., Allan, H., Keir, G. J., Hayen, A., Cooper, W. A., Mahar, A. M., Ellis, S., Macansh, S., & Corte, T. J. (2017). Baseline characteristics of idiopathic pulmonary fibrosis: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 49(2), 1601592.CrossRefPubMed

18.

Lo, L. M. P., Taylor, B. V., Winzenberg, T., Palmer, A. J., Blizzard, L., Ahmad, H., Hussain, M. A., & Van Der Mei, I. (2021). Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis. Journal of Neurology, 268(2), 569–581.CrossRefPubMed

19.

Ahmad, H., van der Mei, I., Taylor, B. V., Campbell, J. A., & Palmer, A. J. (2020). Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. Multiple Sclerosis and Related Disorders, 44, 102358.CrossRefPubMed

20.

Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., Enright, P. L., Hankinson, J. L., Ip, M. S. M., Zheng, J., & Stocks, J. (2012). Multi-ethnic reference values for spirometry for the 3–95-yr age range: The global lung function 2012 equations. European Respiratory Journal, 40(6), 1324–1343.CrossRefPubMed

21.

Stanojevic, S., Graham, B. L., Cooper, B. G., Thompson, B. R., Carter, K. W., Francis, R. W., & Hall, G. L. (2017). Official ERS technical standards: Global lung function Initiative reference values for the carbon monoxide transfer factor for caucasians. European Respiratory Journal, 50(3), 1700010.CrossRefPubMed

22.

Luchman, J. N. (2021). Determining relative importance in stata using dominance analysis: Domin and domme. The Stata Journal: Promoting communications on statistics and Stata, 21(2), 510–538.CrossRef

23.

Azen, R., & Budescu, D. V. (2003). The dominance analysis approach for comparing predictors in multiple regression. Psychological Methods, 8(2), 129–148.CrossRefPubMed

24.

StataCorp. (2021). Stata Statistical Software: Release 17. StataCorp LLC.

25.

Campbell, J. A., Hensher, M., Neil, A., Venn, A., Otahal, P., Wilkinson, S., & Palmer, A. J. (2018). An Exploratory Study: A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D for Long-Term Publicly Waitlisted Bariatric Surgery Patients Before and 3 Months After Bariatric Surgery. PharmacoEconomics - Open, 2(4), 443–458.CrossRefPubMed

26.

Collard, H. R., Ward, A. J., Lanes, S., Cortney Hayflinger, D., Rosenberg, D. M., & Hunsche, E. (2012). Burden of illness in idiopathic pulmonary fibrosis. Journal of Medical Economics, 15(5), 829–835.CrossRefPubMed

27.

Statistics, A. B. o. (2021). Chronic condition multimorbidity, Australian Institute of Health and Welfare. Retrieved October 11, 2022 from https://www.aihw.gov.au/reports/chronic-disease/chronic-condition-multimorbidity/data

28.

Maxwell, A., Özmen, M., Iezzi, A., & Richardson, J. (2016). Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data. Quality of Life Research, 25(12), 3209–3219.CrossRefPubMed

29.

Lodder, M. C. (2004). Bone mineral density in patients with rheumatoid arthritis: Relation between disease severity and low bone mineral density. Annals of the Rheumatic Diseases, 63(12), 1576–1580.CrossRefPubMedPubMedCentral

30.

Ikezoe, K., Handa, T., Tanizawa, K., Kubo, T., Oguma, T., Hamada, S., Watanabe, K., Aihara, K., Sokai, A., Nakatsuka, Y., Muro, S., Nagai, S., Uno, K., Chin, K., Fukui, M., Hirai, T., & Mishima, M. (2015). Bone mineral density in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 109(9), 1181–1187.CrossRefPubMed

31.

Caffarelli, C., Gonnelli, S., Tomai Pitinca, M. D., Francolini, V., Fui, A., Bargagli, E., Refini, R. M., Bennett, D., Nuti, R., & Rottoli, P. (2016). Idiopathic pulmonary fibrosis a rare disease with severe bone fragility. Internal and Emergency Medicine, 11(8), 1087–1094.CrossRefPubMed

32.

Agrawal, A., Verma, I., Shah, V., Agarwal, A., & Sikachi, R. R. (2016). Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable & Rare Diseases Research, 5(2), 70–75.CrossRef

33.

Baumeister, H., Kriston, L., Bengel, J., & Härter, M. (2010). High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. Journal of Clinical Epidemiology, 63(5), 558–565.CrossRefPubMed

34.

King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W. (2014). A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 370(22), 2083–2092.CrossRefPubMed

35.

Richeldi, L., Du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., … Collard, H. R. (2014). Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 370(22), 2071–2082.CrossRefPubMed

36.

Kaunisto, J., Salomaa, E.-R., Hodgson, U., Kaarteenaho, R., Kankaanranta, H., Koli, K., Vahlberg, T., & Myllärniemi, M. (2019). Demographics and survival of patients with idiopathic pulmonary fibrosis in the finnishipf registry. ERJ Open Research, 5(3), 00170–02018.CrossRefPubMedPubMedCentral

Titel: The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument
verfasst von: Qiang Zheng
Ingrid A. Cox
Barbara de Graaff
Julie A. Campbell
Tamera J. Corte
Ian Glaspole
Vidya Navaratnam
Peter Hopkins
Chris Zappala
Hasnat Ahmad
Ting Zhao
Sacha Macansh
E. Haydn Walters
Andrew J. Palmer
Publikationsdatum: 26.12.2022
Verlag: Springer International Publishing
Erschienen in: Quality of Life Research / Ausgabe 6/2023
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-022-03331-8

Springer Professional

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 6/2023

Development of a standard set of PROs and generic PROMs for Dutch medical specialist care

What is important to adults after lower limb reconstruction surgery: a conceptual framework

Psychological interventions improve quality of life despite persistent pain in endometriosis: results of a 3-armed randomized controlled trial

Comparative analysis of pediatric anxiety measures in clinical sample: evaluation of the PROMIS pediatric anxiety short forms

Reliability and validity of the simplified Chinese version of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator

Disagreement between mothers' and fathers' rating of health-related quality of life in children with cancer

Premium Partner